相关实验视频

Updated: Jul 13, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

超声驱动的压电异构结构阻断早期动脉样硬化斑块进展

Junchang Qin¹, Chang Wang¹, Min Di¹

¹Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.

Small (Weinheim an der Bergstrasse, Germany)

|March 17, 2025

概括

新的压电纳米片通过向炎症性巨细胞来治疗动脉样硬化. 这种超声波激活疗法减少了斑块的积累和炎症,为心血管疾病提供了有前途的非侵入性治疗方法.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
心血管研究研究心血管研究

背景情况:

动脉样硬化 (AS) 涉及脂质积累和炎症,导致心血管事件.
巨细胞通过形成泡细胞和促进斑块不稳定性,在AS中发挥关键作用.
目前用于AS的压催化疗法由于低激素生成而具有有限的疗效.

研究的目的:

开发增强的压电BaTiO3 / Ta4C3 MXene异构纳米板 (BTOMX NSs) 用于动脉样硬化治疗.
改善激素的产生和向AS中与炎症相关的巨细胞.
评估BTOMX NSs在阻断早期动脉样硬化斑块进展方面的治疗疗效.

主要方法:

制造BaTiO3 / Ta4C3 MXene异构纳米板 (BTOMX NSs) 的生产.
在超声波照射下评估电子孔分离效率和激素生成.
使用ApoE-/-小鼠进行体内研究,以评估斑块负担,巨细胞透和脂质积累.

主要成果:

BTOMX NSs表现出增强的焦催化活性,具有高的电子孔分离效率.
这些纳米片积聚在动脉样硬化斑块中,并被巨细胞内化.
对BTOMX NSs的超声波刺激引发了巨细胞亡,使斑块负担从21.42%降低到9.04%,并减轻了小鼠的炎症.

结论:

构建异构结构可以提高用于AS治疗的基于BaTiO3的压催化性能.
BTOMX NSs为早期动脉样硬化提供了一种高效,非侵入性和安全的治疗策略.
这种方法提供了一种针对炎症驱动的心血管疾病进展的新方法.

关键词:

这是一个二维的2D.在BATIO3的基础上.这就是MXene MXene.动脉样硬化纳米医学聚焦催化疗法是一种催化疗法.

更多相关视频

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging

Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging

Published on: January 10, 2025

相关概念视频

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...